SARA SWANN: Open Payments
NPI 1003046129 · DANIELSVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$573 in 30 payments from 9 companies in 2025. Trend: 2023 $731 · 2024 $487 · 2025 $573
Food & beverage: $573
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $222 |
| Lundbeck LLC | 4 | $113 |
| ABBVIE INC. | 4 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: Wegovy, VYEPTI, REXULTI, VRAYLAR, JARDIANCE, UBRELVY, Ozempic, MOUNJARO.
Industry payments across GA — which companies pay providers there.
